Contributing to assess the impact of Covid-19 on mental health: our Headway Mental Health Index quoted as reference in EP policy brief

Headway is an initiative on Mental Health that was conceived and launched in 2017 by the think tank The European House Ambrosetti in partnership with Angelini Pharma with the aim of creating a multidisciplinary platform for strategic reflection, analysis, dialogue and comparison between various European experiences in the management of individuals affected by mental disorders.

In 2021, Angelini Pharma in collaboration with the European House Ambrosetti elaborated an analysis model on the performance of European countries in the field of mental health, the Headway 2023 Mental Health Index, with particular focus in the areas of Health, Society, School and Work. The Index was presented during an institutional event on October 7th, 2021 in Brussels. The initiative keeps the trajectory of the programs, activities and strategies of Governments and International Organizations such as the WHO and the UN Sustainable Development Goals, as well as European Institutions with the objective of contributing to reducing the burden of mental disorders in Europe and designing a new roadmap for Mental Health in Europe.

On March 3rd, 2022, the Headway2023 Mental Health Index was quoted as an authoritative reference by the policy brief of the Committee on Women’s Rights and Gender Equality at the European Parliament An ambitious future for Europe's women after COVID-19: mental load, gender equality in teleworking and unpaid care work after the pandemic. The policy brief aims at analyzing the impact of the pandemic on women's mental health compared to men's in Europe, and it is available by clicking on this link.